Two new compounds could reveal hidden drivers of Alzheimer’s disease
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vanderbilt University researchers created VU6083859, the first selective inhibitor of the TAOK1 protein linked to Alzheimer’s disease, enabling precise investigation of its role in neurodegeneration
- Daniel Schultz and Lauren Parr co-led the discovery effort at the Warren Center for Neuroscience Drug Discovery, identifying a compound that uniquely targets TAOK1 without affecting related proteins
- VU6080195, a second compound discovered in the same study, unexpectedly activated all three members of the TAOK protein family, offering a rare tool to study increased TAOK activity in neurological models
- Warren Center for Neuroscience Drug Discovery (WCNDD) leveraged its drug discovery infrastructure to screen structurally varied molecules, leading to both compounds with potential therapeutic research applications
- Craig Lindsley leads the WCNDD and the newly established Vanderbilt Institute for Therapeutic Advances, which supported the research and aims to accelerate neuroscience drug development
- ACS Chemical Neuroscience published the findings on August 3, 2026, detailing the dual discovery of a TAOK1-selective inhibitor and a pan-TAOK activator in a single study
Why it matters: These compounds provide the first tools to independently modulate TAOK1 activity up or down, giving researchers direct experimental control over a poorly understood Alzheimer’s-linked pathway. This advances the ability to test causal biological mechanisms in live models, which could redirect drug development efforts toward previously untestable targets.
